Blackandmed

A higher comorbidity burden was associated with an increased rate of AESI and early discontinuation among patients with MS in clinical trials of DMTs. The post Comorbidity Burden Tied to...

Researchers identified a monocyte/dendritic cell response to EBV reactivation in B cells as one of the earliest events in developing MS relapse. The post Pre-Relapse Immune Signature Implicates EBV Reactivation...

Research found that following a ketogenic diet for 6 months can reprogram immune cell metabolism and promote anti-inflammatory phenotypes in patients with MS. The post Immunomodulatory Potential of Ketogenic Diet...

Results of a post hoc analysis of 3 phase 3 trials of tolebrutinib suggest that PRLs are associated with an increased risk for disability accumulation in MS. The post Paramagnetic...

Participants receiving the potent and highly selective BTK inhibitor fenebrutinib maintained low disease activity in the OLE of the FENopta study. The post MS Activity Remains Low on Long-Term Fenebrutinib...

Research presented at ACC.25 focused on coordination teams and new hospital workflows designed to improve referrals and care quality for cardiology patients. The post Better Workflows Bolster LVAD Care &...

Participants in the novel EAFToS study had high adherence rates to initiation and maintenance doses of ofatumumab in the first interim analysis. The post Ofatumumab: Good Initial Adherence & Treatment...

The post-approval safety profile of cladribine tablets in relapsing MS was updated, with results consistent with development program findings and prior updates. The post Update on Safety Profile of Cladribine...

Researchers found that higher ocrelizumab exposure over 10 years was associated with less risk of disability progression in patients with multiple sclerosis. The post Higher-Dosed Ocrelizumab Associated With Less Disability...

Using the 2024 McDonald Criteria revisions around 30% of patients with atypical clinical symptoms or radiological-only presentation meet MS diagnostic criteria. The post Atypical & Radiological-Only Presentations Often Meet 2024...